Valuation
- Market cap
- 96,394,000
- Revenue TTM
- $189,900,000
- Net income TTM
- $-280,890,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -147.91%
- Debt to equity
- -0.58
Trading
- Volume
- 41,100
- Avg volume
- 94,076
- Day's range
- $3.45 – $3.57
- Shares out
- 27,541,000
- Stochastic %K
- 83%
- Beta
- 2.12
- Analysts
- —
- Price target
- —
Company profile
23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as rep...
Show more
23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. It also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; offers non-controlled medications for treatment of acute and chronic conditions; and provides Ozempic and Wegovy through its weight loss program, offering consumers with access to affordable weight management care. In addition, the company provides research services. 23andMe Holding Co. was founded in 2006 and is headquartered in San Francisco, California.
- Industry
- Diagnostics & Research
- Sector
- Healthcare
- Phone
- 650 938 6300
- Website
- https://www.23andme.com
- Address
- 870 Market Street, Room 415, San Francisco, United States
Latest news
No headlines yet.
